Stock Ratings / Health Care / INMB / insiders

IMA (19) LONA (36) TIL (39) CRBU (33) ⌘ Pro Terminal →

INmune Bio Inc. (INMB) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$1.45 -9.37% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.42

INmune Bio Inc. (INMB) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $44.4M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on INMB Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is INMB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, INmune Bio Inc. (NASDAQ: INMB) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $1.45 (-9.37% 1D, market cap $44.4M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, INMB ranks #820 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does INMB compare to IMA and LONA in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), INMB carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IMA (ImageneBio Inc.) holds a E grade (19/100 RQD, P/E N/A, ROIC -35.0%, cap $46.0M) and LONA (LeonaBio Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $46.3M). Among the 5-stock peer group, INMB leads on earnings multiple (N/A) while INMB leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for INMB?

▼

Per INMB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001711754), INmune Bio Inc. generated $50.0K in revenue (+257.1% YoY), -$46.0M in net income, and -$23.6M in free cash flow against $32.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.42 (-1.88%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.4% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-12.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for INMB)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (31/100 Composite)

🔍 WHY INMB SCORES 31/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+9/20 pts (29% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (26% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$1.78-13.5% Next Q

Q2 (-2Q)

Grade E$1.54-7.1% Next Q

Q3 (-1Q)

Grade E$1.43+1.4% Next Q

Current

Grade E$1.45-9.4% Hist 90D α

Trajectory: E (39) → E (31)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a INMB Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While INMB currently carries a cautious 31/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.98) and Max Pain ($1.52) forces dealer call-delta covering toward $2.73.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $INMB• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “INMB Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 31%NO 69%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

INMB Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (INMB)

No recent open-market Form 4 cluster sales or emergency dumps flagged on INMB. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring INMB)

✓Walkthrough of INMB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

INMB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -2.03%🛡️ HOLDING TREND SUPPORT

2026-11-02O $1.53H $1.60L $1.45C $1.45VOL 185.9K

RES: $3.00SUP: $1.39SMA50: $1.98SMA200: $1.64

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

INMB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 INMB Butterfly Map → + Track INMB →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on INMB today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for INMB. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for INMB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (INMB)

Health Care Rank #820 of 1016 ⚔️ IMA vs INMB Full Matrix →

1. Head-to-Head Health Care Peer Comparison (INMB vs. IMA, LONA, TIL, CRBU)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, INmune Bio Inc. (INMB) ranks #820 by composite RQD confidence (31/100, grade E) and #766 by equity capitalization ($44.4M). Within this direct 5-issuer industry benchmark cohort, INMB leads on earnings valuation at N/A trailing P/E, while INMB leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. TIL currently holds the highest overall quantitative score in the immediate peer group at 39/100 (D-) compared with INMB at 31/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
INMB ACTIVE INmune Bio Inc.	E	31/100	—	—	-35.0%	-9.37%	$44.4M	Benchmark Subject
IMA ImageneBio Inc.	E	19/100	—	—	-35.0%	+1.24%	$46.0M	/ima-vs-inmb →
LONA LeonaBio Inc.	D-	36/100	—	—	-35.0%	+0.61%	$46.3M	/lona-vs-inmb →
TIL Instil Bio Inc.	D-	39/100	—	—	-35.0%	-0.37%	$46.3M	/til-vs-inmb →
CRBU Caribou Biosciences Inc.	E	33/100	—	—	-35.0%	-4.90%	$47.7M	/crbu-vs-inmb →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001711754

In its most recent audited fiscal period (FY2025, filed 2025-12-31), INmune Bio Inc. (INMB) reported GAAP revenue of $50.0K (+257.1% vs. FY2024 revenue of $14.0K , and -67.7% cumulative change since FY2023) , GAAP net income of -$46.0M, operating cash flow of -$22.6M, and free cash flow of -$23.6M (+29.2% YoY). On the balance sheet, INMB closed FY2025 with $32.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$50.0K	-$46.0M	-$22.6M	-$23.6M	$32.4M	—
FY2024 (FY)	2024-12-31	$14.0K	-$42.0M	-$33.4M	-$33.4M	$39.6M	—
FY2023 (FY)	2023-12-31	$155.0K	-$30.0M	-$12.0M	-$12.0M	—	—

3. INMB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is INMB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does INMB compare to IMA and LONA in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for INMB?

Where is INMB trading relative to its 50-day, 200-day, and 52-week technical levels?

INMB last traded at $1.45 (-9.37% on volume of 184,106 shares), positioning the stock -26.77% below its 50-day simple moving average ($1.98) and -11.59% below its 200-day simple moving average ($1.64). Across its 52-week range of $1.09 to $2.60, INMB sits at the 23.8% percentile with a 14-day RSI of 44.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.27 to $1.63).

INMB Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are INMB insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies INMB leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Direct Sub-Reports: INMB RQD Cockpit INMB 12M Forecast INMB Earnings & Move INMB Dividends & DRIP INMB Insiders & 13F INMB Whale Options INMB Profit Sankey INMB News & Why

Sector Peer Dials

Caribou Biosciences Inc.

33 /100

KLRS E

Kalaris Therapeutics Inc.

INMB Core Snapshot

Market Cap $44.4M

Trailing / Fwd P/E — / —

Gross Profit Margin —

Return on Capital (ROIC) -35.0%

Free Cash Flow Yield —

12M Base Price Target $1.27

FREE TRADER TOOLS

Own INMB Alongside Other Stocks? Run a 30-Second Crash X-Ray

Drop 3–5 tickers into our live Portfolio X-Ray to spot hidden accounting time-bombs and see your composite RQD dial.

⚡ X-Ray My Portfolio With INMB → 🏆 Trade INMB in $100K Prop Arena →

INMB Wire

Why It Moved →

Direct Company Event Seeking Alpha • 11h ago

INmune Bio Is A High-Potential Opportunity, But Here's Why I'm Waiting (NASDAQ:INMB)

Peer / Ecosystem Wire Benzinga • 14h ago

Full Transcript: INmune Bio Q2 2026 Earnings Call

Peer / Ecosystem Wire TradingView • 17h ago

INmune Bio Raises $4.5 Million in Stock Offering With Warrants

Direct Company Event Simply Wall St • 20h ago

Is INmune Bio (NASDAQ:INMB) In A Good Position To Deliver On Growth Plans?

Peer / Ecosystem Wire Stock Titan • 23h ago

Third-quarter results and a corporate update are on INmune Bio's Nov. 5 call.

ROARABLE RATING BRIEF • RQD 31/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

INMB — INmune Bio Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:47:20Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, INMB scores 31 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are: Fundamental Cash Engine at 9 / 20 (ROIC -35%; FCF yield 0%), Whale 13F Flow at 5 / 20 (institutional accumulation and options positioning), Insider Conviction at 3 / 20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 6 / 20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 8 / 20 (Altman Z 2.5; Piotroski F 3/9; Debt/Equity 0.5).

For a prospective investor, the lowest-scoring pillars are the most informative. The insider conviction score of 3 / 20 indicates weak insider signaling in the provided data, and the whale flow score of 5 / 20 indicates limited institutional accumulation. The cash engine score reflects negative returns on invested capital and zero free-cash-flow yield, meaning the business is not currently generating returns on capital. The forensic balance sheet score is moderate-to-weak, with a Piotroski F-Score of 3 out of 9. Upside drivers would have to come from catalysts outside the financial record in this dossier; the source data does not quantify such drivers. Valuation tradeoffs are difficult to assess because forward and trailing earnings multiples are not available in source data, so the market price cannot be benchmarked against earnings. The macro pillar at 6 / 20 with Beta 1.0 indicates the stock moves in line with the broader market rather than offering a defensive profile. This brief is analytical and educational, not personalized financial advice.

Business

INmune Bio Inc. is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry. Per the profile, the company's market capitalization is $0.0B on the profile's rounding. Customer base, product lines, and revenue model are not described in the source data. The reported revenue figures are small, at $0.1M in FY 2025, $0.0M in FY 2024, and $0.2M in FY 2023.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$0.1M	$-47.4M	$-46.0M	N/A	$-23.6M	$24.8M	N/A
FY 2024	$0.0M	$-42.6M	$-42.0M	N/A	$-33.4M	$20.9M	N/A
FY 2023	$0.2M	$-29.7M	$-30.0M	N/A	$-12.0M	N/A	N/A

Per the SEC financials, the company reported operating losses in each period shown, with operating margin at -60% and net margin at -60% in the market data, and gross margin at 0%. ROIC is -35% and FCF yield is 0%. The Altman Z-Score is 2.5 and the Piotroski F-Score is 3 out of 9, both per the Roarable RQD rating. Debt/Equity is 0.5 per the same rating. Reported cash rose from $20.9M in FY 2024 to $24.8M in FY 2025, while reported debt is N/A in the source data.

Recent Catalysts & News Wire Analysis

Per the recent news section, the headlines are as follows. A Seeking Alpha piece titled "INmune Bio Is A High-Potential Opportunity, But Here's Why I'm Waiting" is flagged YELLOW as market wire. A Benzinga item, "Full Transcript: INmune Bio Q2 2026 Earnings Call," is flagged YELLOW as market wire. A TradingView item, "INmune Bio Raises $4.5 Million in Stock Offering With Warrants," is flagged GREEN as a catalyst. A Simply Wall St item, "Is INmune Bio (NASDAQ:INMB) In A Good Position To Deliver On Growth Plans?," is flagged GREEN as a catalyst. A Stock Titan item says third-quarter results and a corporate update are scheduled for a Nov. 5 call and is flagged YELLOW as market wire. A second Stock Titan item, "A quantum-computing company gets its first customer in pharma and biotech: INmune Bio," is flagged YELLOW as market wire.

Risk watch items include the $4.5 million stock offering with warrants, which is a dilution-related event, and the upcoming Nov. 5 earnings call. The Butterfly Supply-Chain Graph reports no proprietary signals and no butterfly links.

Open Questions

What are the company's specific products, approved indications, and revenue sources, given that reported revenue is only $0.1M in FY 2025?
What is the current cash runway relative to the FY 2025 operating loss of $-47.4M, and how will the $4.5 million offering affect dilution?
What are the terms and share count implications of the warrants attached to the recent stock offering?
What are the trailing and forward earnings multiples, given that P/E and EPS are not available in source data?
What was the outcome of the Q2 2026 earnings call and what will the Nov. 5 third-quarter results show?

INMB Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for INmune Bio Inc. (INMB) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to INMB Debate Forum (3) ↓

🟡 MARKET WIRE Seeking Alpha • 11h ago

INmune Bio Is A High-Potential Opportunity, But Here's Why I'm Waiting (NASDAQ:INMB)

Seeking Alpha report covering INmune Bio Inc. (INMB) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 14h ago

Full Transcript: INmune Bio Q2 2026 Earnings Call

Benzinga report covering INmune Bio Inc. (INMB) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST TradingView • 17h ago

INmune Bio Raises $4.5 Million in Stock Offering With Warrants

TradingView report covering INmune Bio Inc. (INMB) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Simply Wall St • 20h ago

Is INmune Bio (NASDAQ:INMB) In A Good Position To Deliver On Growth Plans?

Simply Wall St report covering INmune Bio Inc. (INMB) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 23h ago

Third-quarter results and a corporate update are on INmune Bio's Nov. 5 call.

Stock Titan report covering INmune Bio Inc. (INMB) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

A quantum-computing company gets its first customer in pharma and biotech: INmune Bio

Stock Titan report covering INmune Bio Inc. (INMB) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 1d ago

INmune Bio (INMB) Slips 3.61% to $1.87 as Shares Drift Toward Support at $1.78 - Double EMA

https://www.siam.in/ report covering INmune Bio Inc. (INMB) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE ad-hoc-news.de • 1d ago

INmune Bio stock sits 36.15 percent below its Nasdaq high

ad-hoc-news.de report covering INmune Bio Inc. (INMB) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

INMB Bull vs. Bear Conversation Board — What's Your Call at $1.45?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON INMB 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $1.41 (-11.9%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is INMB (E • RQD 31/100) a Buy at $1.60?

Welcome to the INMB (INmune Bio Inc.) Roar Pit. Current RQD Composite is 31/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SK SkepticalCFA Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $1.34 (-16.3%)

Spot @ $1.60

Pump the brakes on INMB — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on INMB, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless INmune Bio Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

TA TapeReader_Pro Verified K Arena Trader 🐂 BULLISH 🎯 Target: $1.98 (+23.7%)

Spot @ $1.60

INMB cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on INMB, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $1.60 (52-wk range $1.09 - $2.60), any beat on forward guidance forces shorts and underweight funds to chase.